CNBX Pharmaceuticals (CNBX Pharmaceuticals) Total Inventories : $0.00 Mil (As of Feb. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Total Inventories?

CNBX Pharmaceuticals's total inventories for the quarter that ended in Feb. 2024 was $0.00 Mil. CNBX Pharmaceuticals's average total inventories from the quarter that ended in Nov. 2023 to the quarter that ended in Feb. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. CNBX Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Feb. 2024 was $-0.08.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. CNBX Pharmaceuticals's Days Inventory for the three months ended in Feb. 2024 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CNBX Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Feb. 2024 was 0.00.

CNBX Pharmaceuticals Total Inventories Historical Data

The historical data trend for CNBX Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Total Inventories Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Total Inventories

Get a 7-Day Free Trial

CNBX Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

CNBX Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

CNBX Pharmaceuticals (OTCPK:CNBX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

CNBX Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Feb. 2024 is

	Net-Net Working Capital Per Share (Q: Feb. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.037	+	0.75 * 0	+	0.5 * 0	-	2.522
-	0	-	0)	/	31.1113
=	-0.08

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CNBX Pharmaceuticals's Days Inventory for the three months ended in Feb. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Feb. 2024 )	/	Cost of Goods Sold (Q: Feb. 2024 )	*	Days in Period
	=	0	/	0.007	*	365 / 4
	=	0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

CNBX Pharmaceuticals's Inventory Turnover for the quarter that ended in Feb. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Feb. 2024 )	/	Average Total Inventories (Q: Feb. 2024 )
	=	0.007	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CNBX Pharmaceuticals's Inventory to Revenue for the quarter that ended in Feb. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	0	/	0.041
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

CNBX Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary